Document:

EX-10.19

 Exhibit 10.19 

December 17, 2013 

CONFIDENTIAL 
 Timothy C. Rodell, M.D., FCCP 

President and CEO 
 GlobeImmune, Inc. 

1450 Infinite Drive 
 Louisville, CO 80027 

 

	 	Re:	Initial Public Offering 

 Dear Tim: 

The purpose of this engagement letter is to outline our agreement in principle pursuant to which Aegis Capital Corp. (“Aegis”)
will act as the lead underwriter on a firm commitment basis in connection with the proposed initial public offering (the “Offering”) of common stock (the “Common
Stock”) by GlobeImmune, Inc. (collectively, with its subsidiaries and affiliates, the “Company”). This engagement letter sets forth certain conditions and assumptions upon which the
Offering is premised. However, except as expressly provided herein, this engagement letter is not intended to be a binding legal document, as the agreement between the parties hereto on the matters relating to the Offering will be embodied in the
Underwriting Agreement (as defined below). 
 The terms of our agreement in principle are as follows: 

The Company hereby engages Aegis, for the period beginning on the date hereof and ending on the earlier of (i) six (6) months from the date of the
initial closing of the Debt Placement (as defined below) or (ii) completion of the Offering, unless sooner terminated pursuant to the terms of this engagement letter (the “Engagement Period”), to act
as the Company’s lead managing underwriter and/or book runner and investment banker in connection with the proposed Offering or any other equity or debt financing. Notwithstanding the foregoing, an Offering will not include (and Aegis will not
be entitled to a fee) if, during the Engagement Period, the Company completes (i) licensing or collaboration transactions, including such transactions which have debt or equity components, (ii) ordinary course debt and (iii) any
merger, reorganization, consolidation, acquisition of 50% or more of the voting power of the Company or acquisition of substantially all of the assets of the Company. 

1. If requested by the Company and reasonably appropriate to this engagement, during the engagement, Aegis will provide the following services
to the Company in connection with a possible Offering: 
  

	 	•	 	Aegis will familiarize itself with the business, operations, properties, financial condition and prospects of the Company such that it can assist with the Offering; 

 

	 	•	 	Aegis will advise and assist the Company in evaluating any potential Offering, and, if the Company believes such Offering to be desirable, advise the Company regarding a general strategy and process for completing the
Offering; 

  

	 	•	 	Aegis will contact potential investors and may meet with representatives of investors and provide them with such information about the Company as may be appropriate, subject to customary confidentiality and legal
restrictions; and 

  

	 	•	 	Aegis will, if requested by the Company and when deemed necessary, assist in evaluation of terms, formulate negotiation strategies and assist in negotiations in connection with an Offering. 

 2. The Offering will consist of the sale of approximately $40 million worth of common stock of
the Company (“Common Stock”) (the shares of Common Stock to be sold in the Offering are hereinafter referred to collectively as the “Shares”). Aegis will act as lead managing underwriter
of an underwriting syndicate, subject to, among other matters referred to herein and additional customary conditions, completion of Aegis’ due diligence examination of the Company and its affiliates, and the execution of a definitive
underwriting agreement between the Company and Aegis in connection with the Offering (the “Underwriting Agreement”). The Company and Aegis will agree to: (i) create an underwriting syndicate for the
Offering comprised of broker-dealers who are members of the Financial Industry Regulatory Authority (“FINRA”) and mutually agreed upon by both the Company and Aegis, (ii) rely on soliciting dealers
who are FINRA members to participate in placing a portion of the Offering, (iii) offer Shares to such dealers at less than the public offering price and/or (iv) offer Shares in foreign jurisdictions. 

3. The actual size of the Offering, the precise number of Shares to be offered by the Company and the offering price per Share will be the
subject of continuing negotiations between the Company and Aegis and will depend upon, among other factors: (i) the capitalization of the Company at the time of the Offering, (ii) market and general economic conditions and changes in the
prospects and/or forecasts of the Company, (iii) the preparation and Aegis’ review of the Company’s audited financial statements, (iv) Aegis’ determination of the Company’s pre-money valuation (based upon the
information provided to Aegis by the Company) and (v) other factors. This agreement does not constitute an agreement or commitment (express or implied) on the part of the Company to enter into or consummate an
Offering, and nothing in this agreement shall prevent the Company from abandoning or otherwise electing not to proceed with any Offering. The Company shall have sole discretion in determining whether or not to proceed with an Offering. Accordingly,
Aegis has no power to enter into any agreement or incur any obligation on behalf of the Company without the Company’s prior written consent. 

4. The Underwriting Agreement will provide that the Company will grant to Aegis an option, exercisable within 45 days after the closing of the
Offering (“Closing”), to acquire up to an additional 15% of the total number of Shares to be offered by the Company in the Offering, solely for the purpose of covering over-allotments (the “Over-allotment Shares”).

 5. The Company will pay an underwriting discount or spread of 7.0% of the public offering. Aegis and any other underwriters will also be
entitled to a pro-rata non-accountable expense allowance equal to 1% of the public offering price. The Company shall pay a $25,000 advance to Aegis upon execution of this engagement letter (“Advance”), which shall be applied against the
underwriting discount. As additional compensation for Aegis’ services, the Company shall issue to Aegis or its designees at the Closing warrants (the “Underwriter’s Warrants”) to purchase that number of shares of Common
Stock equal to 2% of the aggregate number of Shares sold in the Offering. The Underwriter’s Warrants will be exercisable at any time and from time to time, in whole or in part, during the four-year period commencing one year from the Closing,
at a price per share equal to 150.0% of the public offering price per share of common stock at the Offering. The Underwriter’s Warrant will provide for registration rights (including piggyback rights for up to two registration statements) and
customary anti-dilution provisions (for stock dividends and splits and recapitalizations) consistent with FINRA Rule 5110, and further, the number of shares underlying the Underwriter’s Warrants shall be reduced if necessary to comply with
FINRA rules or regulations. 

  
 - 2 - 

 6. The Company will, as soon as practicable following the date hereof, prepare and, following
completion of the contemplated convertible debt offering with Aegis acting as placement agent with gross proceeds to the Company of at least $5,000,000 (the “Debt Placement”), file with the Securities and Exchange Commission (the
“Commission”) and the appropriate state securities authorities, a Registration Statement on Form S-1 (the “Registration Statement”) under the Securities Act of 1933, as amended (the “Act”), and a
prospectus included therein (the “Prospectus”) covering the Shares to be sold in the Offering and the Over-allotment Shares. The Registration Statement (including the Prospectus therein), and all amendments and supplements thereto,
will be in form reasonably satisfactory to Aegis and counsel to Aegis and will contain: (i) audited financial statements of the Company and such interim and other financial statements and schedules as may be required by the Act and rules and
regulations of the Commission thereunder, and (ii) a description of the business of the Company and such other disclosures regarding the Company and its officers and directors as may be required by the Act and rules and regulations of the
Commission thereunder. 
 7. The Registration Statement filing will include as an exhibit a proposed form of Underwriting Agreement. The
final Underwriting Agreement will be in form satisfactory to the Company and Aegis and will include indemnification provisions and other terms and conditions customarily found in underwriting agreements for initial public offerings. Without limiting
the generality of the foregoing, the Underwriting Agreement will contain customary representations and warranties of the Company and will further provide, in addition to the matters addressed herein, that (i) the Company’s directors and
officers and any other holder of outstanding shares of Common Stock as of the effective date of the Registration Statement, will enter into customary “lock-up” agreements, including customary carve outs, in favor of Aegis pursuant to which
such persons and entities will agree, for a period of six (6) months from the date of the Offering, that they will neither offer, issue, sell, contract to sell, encumber, grant any option for the sale of or otherwise dispose of any securities
of the Company without Aegis’ prior written consent and (ii) each of the Company and any successors of the Company will agree, for a period of six (6) months from the Closing, that, subject to customary carve outs, each will not
(a) offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, lend, or otherwise transfer or dispose of, directly or indirectly, any
shares of capital stock of the Company or any securities convertible into or exercisable or exchangeable for shares of capital stock of the Company; (b) file or caused to be filed any registration statement with the Commission relating to the
offering of any shares of capital stock of the Company or any securities convertible into or exercisable or exchangeable for shares of capital stock of the Company other than Registration Statements on Form S-8 or (c) enter into any swap or
other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of capital stock of the Company, whether any such transaction described in clause (a), (b) or (c) above is to be settled by
delivery of shares of capital stock of the Company or such other securities, in cash or otherwise. 
 8. Concurrently with or as soon as
practicable after the filing of the Registration Statement with the Commission, the Company will make all necessary state “blue sky” securities law filings with respect to the Shares to be sold in the Offering (including the Over-allotment
Shares). The Company and Aegis will cooperate in obtaining the necessary approvals and qualifications in such states as Aegis and the Company deem necessary and/or desirable. It is agreed that Aegis’ counsel will act as the Company’s
“blue sky” counsel with respect to this Offering. The Company will be responsible for and pay certain expenses relating to the Offering, including, without limitation, (a) all filing fees and communication expenses relating to the
registration of the Shares to be sold in the Offering (including the Over-allotment Shares) with the Commission; (b) all COBRADesk filing fees associated with the review of the Offering by FINRA; all fees and expenses relating to the listing of
such Shares on the Nasdaq Capital Market, the Nasdaq Global Market, Nasdaq Global Select Market or the NYSE Amex and on such other stock exchanges as the Company and Aegis together determine; (c) all fees, expenses and disbursements relating to
background 

  
 - 3 - 

 
checks of the Company’s officers and directors in an amount not to exceed $25,000 in the aggregate; (d) all fees, expenses and disbursements relating to the registration or
qualification of such Shares under the “blue sky” securities laws of such states and other jurisdictions as the Company and Aegis may reasonably agree (including, without limitation, all filing and registration fees, and the reasonable
fees and disbursements of “blue sky” counsel, it being agreed that such fees and expenses will be limited to: (i) if the Offering is commenced on either the Nasdaq Global Market, Nasdaq Global Select Market or the NYSE Amex, the
Company will make a payment of $5,000 to such counsel at Closing or (ii) if the Offering is commenced on the Nasdaq Capital Market or on the Over the Counter Bulletin Board, the Company will make a payment of $15,000 to such counsel upon the
commencement of “blue sky” work by such counsel and an additional $5,000 at Closing); (e) all fees, expenses and disbursements relating to the registration, qualification or exemption of such Shares under the securities laws of such
foreign jurisdictions as the Company and Aegis may reasonably agree; (f) fees and expenses of the transfer agent for the Common Stock; (g) stock transfer and/or stamp taxes, if any, payable upon the transfer of securities from the Company
to Aegis; (h) the costs associated with post-Closing advertising the Offering in the national editions of the Wall Street Journal and New York Times; provided that, such amounts will not exceed $5,000 without the Company’s prior
written consent; (i) the fees and expenses of the Company’s accountants; (j) the fees and expenses of the Company’s legal counsel and other agents and representatives; (k) the $21,775 cost associated with the use of
Ipreo’s book building, prospectus tracking and compliance software for the Offering; provided that, such fee or portion thereof is only payable upon closing of an Offering; (l) the fees and expenses of the Underwriter’s legal
counsel not to exceed $75,000 provided that, such fees and expenses or portion thereof is only payable upon closing of an Offering; and (m) up to $20,000 of Aegis’ actual accountable “road show” expenses for the Offering;
provided that, such fee or portion thereof is only payable in connection with the closing of the Offering. 
 9. While the Commission
is reviewing the Registration Statement, Aegis will plan and arrange one or more “road show” marketing trips for the Company’s management to meet with prospective investors. Such trips will include visits to a number of prospective
institutional and retail investors. The Company will pay for its own expenses, including, without limitation, the costs of recording and hosting on the Internet of the Company’s road show presentation and travel and lodging expenses associated
with such trips; provided that, such amounts will not exceed $20,000 without the Company’s prior written consent. During the 45-day period prior to the filing of the Registration Statement with the Commission, and at all times thereafter
prior and following the effectiveness of the Registration Statement, the Company, its officers, directors and related parties and Aegis and its officers, directors and related parties will abide by all rules and regulations of the Commission
relating to public offerings, including, without limitation, those relating to public statements (i.e., “gun jumping”) and disclosures of material non-public information. In addition, neither Aegis or the Company will , without the prior
written consent of the other party, make any offer relating to the Shares that would constitute an “issuer free writing prospectus,” as defined in Rule 433 under the Securities Act, or that would otherwise constitute a “free writing
prospectus,” as defined in Rule 405 under the Securities Act required to be filed with the Commission. 
 10. At such time as the
Company and Aegis are mutually satisfied that it is appropriate to commence the Offering, the final terms of the Underwriting Agreement will be negotiated and the Company and Aegis will request the Commission to make the Registration Statement
effective. 
 11. The Offering will be conditioned upon, among other things, the following: 

(a) Satisfactory completion by Aegis of its due diligence investigation and analysis of: (i) the Company’s arrangements with its
officers, directors, employees, affiliates, customers and suppliers and (ii) the Company’s audited historical financial statements as may be required by the Securities Act and rules and regulations of the Commission thereunder for
inclusion in the Registration Statement, and approval by Aegis’ commitment committee; 

  
 - 4 - 

 (b) The execution by the Company and Aegis of a definitive Underwriting Agreement containing all
applicable terms and conditions provided for in this engagement letter; 
 (c) The Company meeting the criteria necessary for inclusion of
the Common Stock on the Nasdaq Capital Market, Nasdaq Global Market, Nasdaq Global Select Market or the NYSE Amex and seeking and using its commercially reasonable efforts to maintain such listing for a period of at least three years after the
Closing; 
 (d) Neither the Company nor any of its affiliates having, either prior to the initial filing or the effective date of the
Registration Statement, made any offer or sale of any securities which are required to be “integrated” pursuant to the Act or the regulations thereunder with the offer and sale of the Shares pursuant to the Registration Statement; 

(e) The Company’s registration of the Common Stock under the provisions of Section 12(b) or (g), as applicable, of the Securities
Exchange Act of 1934, as amended (the “Exchange Act”) on or prior to the effective date of the Offering; 
 (f) The Company
retaining an independent certified public accounting firm, which will have responsibility for the preparation of the financial statements and the financial exhibits, if any, to be included in the Registration Statement; and 

(g) The Company retaining a transfer agent for the Company’s Common Stock. 

12. (a) Except as provided in Paragraphs 1, 5, 12, 13, 15, 18, 19 and 20 hereof (which Paragraphs are intended to be legally binding and
enforceable on and against the Company and Aegis), this engagement letter is not intended to be a binding legal document nor a legal commitment on the part of Aegis to provide any financing to the Company, as the agreement between the parties hereto
on these matters will be embodied in the Underwriting Agreement. Until the Underwriting Agreement has been finally negotiated and signed, the Company or Aegis may at any time terminate their further participation in the proposed transactions
contemplated hereby and the engagement by the Company of Aegis, and the party so terminating will have no liability to the other on account of any matters provided for herein, except as provided for in this Paragraph. 

(b) Regardless of which party elects to terminate their further participation in the proposed transactions contemplated hereby and the
engagement by the Company of Aegis, upon such termination, the Company agrees to reimburse Aegis for, or otherwise pay and bear, the expenses and fees to be paid and borne by the Company as provided for in Paragraph 8 above and to reimburse Aegis
for the full amount of its actual, reasonable, documented out of pocket accountable expenses as described in Section 8 incurred to such date up to a maximum of $100,000 (provided, however, that such expense cap in no way limits or impairs the
indemnification and contribution provisions of this engagement letter) less amounts, if any, previously paid to Aegis in reimbursement for such expenses; provided, however, that Aegis will not be entitled to any such reimbursement if:
(i) Aegis terminates Aegis’ engagement prior to the execution of the Underwriting Agreement for other than Good Reason (as defined below) (ii) the Company terminates Aegis’ engagement prior to the execution of the Underwriting
Agreement on account of Aegis’ gross negligence, willful misconduct or breach of this Agreement, (iii) the Debt Placement has not been completed by February 28, 2014, (iv) the Company terminates Aegis engagement prior to the
execution of the Underwriting Agreement for Aegis’ failure to proceed with the Offering in good faith. 
 (c) As used herein, the term
“Good Reason” means: (i) the failure of the Company to proceed with the Offering in good faith, (ii) the gross negligence or willful misconduct of the Company, (iii) the occurrence of any domestic or international
event or act or occurrence which materially disrupts, or in Aegis’ sole opinion will, in the immediate future, materially disrupt, general 

  
 - 5 - 

 
securities markets in the United States for a period greater than one month, (iv) the Company will have sustained a material loss by fire, flood, accident, hurricane, earthquake, theft,
sabotage or other calamity or malicious act which, is not covered by adequate insurance proceeds, will, in Aegis’ sole judgment, make it substantially impossible to proceed with the Offering; (v) a material adverse change in the condition
of the Company which would make it, in Aegis’ sole judgment substantially impossible to proceed with the Offering. 
 13. The Company
represents to Aegis that the Company is or will be liable for any finder’s fees to third parties in connection with the introduction of the Company to Aegis. The Company represents and warrants to Aegis that the entry into this engagement
letter or any other action of the Company in connection with the proposed Offering will not violate any agreement between the Company and any other underwriter. Aegis reserves the right to reduce any item of its compensation or adjust the terms
thereof as specified herein in the event that a determination and/or suggestion will be made by FINRA to the effect that the underwriters’ aggregate compensation is in excess of FINRA rules or that the terms thereof require adjustment;
provided, however, the aggregate compensation otherwise to be paid to the underwriters by the Company may not be increased above the amounts stated herein without the written approval of the Company. 

14. Neither the Company nor any of its affiliates has either prior to the initial filing or the effective date of the Registration Statement,
made any offer or sale of any securities which are required to be “integrated” pursuant to the Act or the regulations thereunder with the offer and sale of the Shares pursuant to the Registration Statement. 

15. Neither Aegis nor the Company agrees will issue press releases or engage in any other publicity, without the other party’s prior
written consent, commencing on the date hereof and continuing for a period of forty (40) days from Closing of the Offering, other than normal and customary releases issued in the ordinary course of the Company’s business. The Company and
Aegis covenant to adhere to all “gun jumping” and “quiet period” rules and regulations of the Commission prior to, during and following the filing of the Registration Statement and the consummation of the Offering. 

16. During the Engagement Period or until the Closing, the Company agrees to cooperate with Aegis and to furnish, or cause to be furnished, to
Aegis, any and all information and data concerning the Company, and the Offering that Aegis reasonably requests (the “Information”). The Company will provide Aegis reasonable access during normal business hours from and after the
date of execution of this Agreement until the date of the Closing to all of the Company’s assets, properties, books, contracts, commitments and records and to the Company’s officers, directors, employees, appraisers, independent
accountants, legal counsel and other consultants and advisors. The Company represents and warrants to Aegis that all Information: (i) contained in any preliminary or final Prospectus prepared by the Company in connection with the Offering, and
(ii) contained in any filing by the Company with any court or governmental regulatory agency, commission or instrumentality, will be complete and correct in all material respects and will not contain any untrue statement of a material fact or
omit to state a material fact necessary to make the statements therein not misleading in the light of the circumstances under which such statements are made. The Company acknowledges and agrees that in rendering its services hereunder, Aegis will be
using and relying on such Information (and information available from public sources and other sources deemed reliable by Aegis) without independent verification thereof by Aegis or independent appraisal by Aegis of any of the Company’s assets.
The Company acknowledges and agrees that this engagement letter and the terms hereof are confidential and will not be disclosed to anyone other than the officers and directors of the Company and the Company’s accountants, advisors and legal
counsel or as required by law or regulation. Except as contemplated by the terms hereof or as required by applicable law, Aegis will keep strictly confidential all non-public Information concerning the Company provided to Aegis as more fully
described in the Non-Disclosure Agreement dated as of May 3, 2013 between Aegis and the Company. By execution of this letter, Aegis and the Company agree that the term of such Non-Disclosure Agreement is hereby extended until December 31,
2014. 

  
 - 6 - 

 17. The Underwriting Agreement will provide that for a period of twelve (12) months from the
Closing, the Company will grant to Aegis the right of first refusal to act as a bookrunner with at least forty two and one half (42.5) percent of the economics for the first public or private equity or public debt offering during such twelve
(12) month period of the Company, or any successor to or any subsidiary of the Company. 
 18. This engagement letter does not create,
and shall not be construed as creating rights enforceable by any person or entity not a party hereto, except those entitled hereto by virtue of the indemnification provisions hereof. The Company acknowledges and agrees that Aegis is not and shall
not be construed as a fiduciary of the Company and shall have no duties or liabilities to the equity holders or the creditors of the Company or any other person by virtue of this engagement letter or the retention of Aegis hereunder, all of which
are hereby expressly waived. 
 19. (a) To the extent permitted by law, the Company will indemnify Aegis and its affiliates,
stockholders, directors, officers, employees, members and controlling persons (within the meaning of Section 15 of the Securities Act or Section 20 of the Exchange Act) against all out of pocket losses, claims, damages, expenses and
liabilities, as the same are incurred (including the reasonable fees and expenses of counsel), relating to or arising out of its activities hereunder or pursuant to this engagement letter, except to the extent that any losses, claims, damages,
expenses or liabilities (or actions in respect thereof) are found in a final judgment (not subject to appeal) by a court of law to have resulted primarily and directly from Aegis’ willful misconduct or gross negligence in performing the
services described herein. 
 (b) Promptly after receipt by Aegis of notice of any claim or the commencement of any action or proceeding
with respect to which Aegis is entitled to indemnity hereunder, Aegis will notify the Company in writing of such claim or of the commencement of such action or proceeding, but failure to so notify the Company shall not relieve the Company from any
obligation it may have hereunder, except and only to the extent such failure results in the forfeiture by the Company of substantial rights and defenses. If the Company so elects or is requested by Aegis, the Company will assume the defense of such
action or proceeding and will employ counsel reasonably satisfactory to Aegis and will pay the reasonable fees and expenses of such counsel. Notwithstanding the preceding sentence, Aegis will be entitled to employ counsel separate from counsel for
the Company and from any other party in such action if counsel for Aegis reasonably determines that it would be inappropriate under the applicable rules of professional responsibility for the same counsel to represent both the Company and Aegis. In
such event, the reasonable fees and disbursements of no more than one such separate counsel will be paid by the Company, in addition to local counsel. The Company will have the exclusive right to settle the claim or proceeding provided that the
Company will not settle any such claim, action or proceeding without the prior written consent of Aegis, which will not be unreasonably withheld. 

(c) The Company agrees to notify Aegis promptly of the assertion against it or any other person of any claim or the commencement of any action
or proceeding relating to a transaction contemplated by this engagement letter. 
 (d) If for any reason the foregoing indemnity is
unavailable to Aegis or insufficient to hold Aegis harmless, then the Company shall contribute to the amount paid or payable by Aegis as a result of such losses, claims, damages or liabilities in such proportion as is appropriate to reflect not only
the relative benefits received by the Company on the one hand and Aegis on the other, but also the relative fault of the Company on the one hand and Aegis on the other that resulted in such losses, claims,

  
 - 7 - 

 
damages or liabilities, as well as any relevant equitable considerations. The amounts paid or payable by a party in respect of losses, claims, damages and liabilities referred to above shall be
deemed to include any reasonable legal or other fees and expenses incurred in defending any litigation, proceeding or other action or claim. Notwithstanding the provisions hereof, Aegis’ share of the liability hereunder shall not be in excess
of the amount of fees actually received, or to be received, by Aegis under this engagement letter (excluding any amounts received as reimbursement of expenses incurred by Aegis). 

(e) These indemnification provisions shall remain in full force and effect whether or not the transaction contemplated by this engagement
letter is completed and shall survive the termination of this engagement letter, and shall be in addition to any liability that the Company might otherwise have to any indemnified party under this engagement letter or otherwise. 

20. The Company represents that it is free to enter into this engagement letter and the transactions contemplated hereby, that it will act in
good faith, and that it will not hinder Aegis’ efforts hereunder. This engagement letter will be deemed to have been made and delivered in New York City and both the binding provisions of this engagement letter and the transactions contemplated
hereby and by the Underwriting Agreement will be governed as to validity, interpretation, construction, effect and in all other respects by the internal laws of the State of New York, without regard to the conflict of laws principles thereof. Each
of Aegis and the Company: (i) agrees that any legal suit, action or proceeding arising out of or relating to this engagement letter and/or the transactions contemplated hereby will be instituted exclusively in New York Supreme Court, County of
New York, or in the United States District Court for the Southern District of New York, (ii) waives any objection which it may have or hereafter to the venue of any such suit, action or proceeding, and (iii) irrevocably consents to the
jurisdiction of the New York Supreme Court, County of New York, and the United States District Court for the Southern District of New York in any such suit, action or proceeding. Each of the Underwriter and the Company further agrees to accept and
acknowledge service of any and all process which may be served in any such suit, action or proceeding in the New York Supreme Court, County of New York, or in the United States District Court for the Southern District of New York and agrees that
service of process upon the Company mailed by certified mail to the Company’s address will be deemed in every respect effective service of process upon the Company, in any such suit, action or proceeding, and service of process upon Aegis
mailed by certified mail to Aegis’ address will be deemed in every respect effective service process upon Aegis, in any such suit, action or proceeding. Notwithstanding any provision of this engagement letter to the contrary, the Company agrees
that neither Aegis nor its affiliates, and the respective officers, directors, employees, agents and representatives of Aegis, its affiliates and each other person, if any, controlling Aegis or any of its affiliates, will have any liability (whether
direct or indirect, in contract or tort or otherwise) to the Company for or in connection with the engagement and transaction described herein except for any such liability for losses, claims, damages or liabilities incurred by us that are finally
judicially determined to have resulted from the bad faith or gross negligence of such individuals or entities. Aegis will act under this engagement letter as an independent contractor with duties to the Company. 

  
 - 8 - 

 We are delighted at the prospect of working with you and look forward to a successful Offering.
If you are in agreement with the foregoing, please sign and return to us one copy of this engagement letter together with a payment to Aegis Capital Corp. in the amount of twenty-five thousand dollars $25,000 for the Advance. This engagement letter
may be executed in counterparts (including facsimile or .pdf counterparts), each of which shall be deemed an original but all of which together shall constitute one and the same instrument. 

 

			
	 Yours truly,
  

AEGIS CAPITAL CORP.

		
	By:	 	/s/ George Kott
		 	 Name: George Kott
 Title: COO

 Accepted and agreed to as of 

the date first written above: 
  

			
	GLOBEIMMUNE, INC.
		
	By:	 	/s/ Timothy C. Rodell
		 	 Name: Timothy C. Rodell, M.D., FCCP
 Title:
President and CEO

  
 - 9 -EX-10.20

 Exhibit 10.20 

PLACEMENT AGENCY AGREEMENT 

January 27, 2014 
 Aegis Capital Corp. 

810 Seventh Ave, 11th Floor 
 New York, NY 10019 

 

	Re:	GlobeImmune, Inc. 

 Ladies and Gentlemen: 

This Placement Agency Agreement (“Agreement”) sets forth the terms upon which Aegis Capital Corp., a New York corporation, and
a registered broker-dealer and member of the Financial Industry Regulatory Authority (“FINRA”) (the “Placement Agent”), shall be engaged by GlobeImmune, Inc., a Delaware corporation (the “Company”),
to act as its exclusive Placement Agent in connection with the private placement (the “Offering”) of units (“Units”) of securities of the Company, each Unit consisting of (i) a 10% Convertible Term Note in a
principal amount of $250,000 (each, a “Note” and collectively, the “Notes”), convertible into securities of the Company determined as set forth in the Notes, and (ii) a warrant (each, a
“Warrant” and collectively, the “Warrants”), with each Warrant entitling the holder to purchase $250,000 of securities of the Company determined as set forth in the Warrants. The Offering will consist of a maximum
of 20 Units ($5,000,000) (the “Maximum Amount”). If the Offering is over-subscribed, upon mutual agreement of Placement Agent and the Company, the Company may sell up to an additional 20 Units ($5,000,000) to cover such
over-subscriptions. 
 The purchase price for the Units will be $250,000 per Unit (the “Offering Price”), with a minimum
per subscriber investment of one Unit; provided, however, that subscriptions for lesser amounts may be accepted in the Company’s discretion. The Placement Agent shall offer Units only to persons or entities who qualify as
“accredited investors,” as such term is defined in Rule 501 of Regulation D (“Regulation D”) as promulgated by the United States Securities and Exchange Commission (the “SEC”) under Section 4(a)(2) of
the Securities Act of 1933, as amended (the “Act”). The Units will be offered during the period (such period, the “Offering Period”) beginning on the date of the Memorandum (as defined below) and ending on the
earlier of (i) the termination of the Offering as provided herein, (ii) the time that all Units offered in the Offering are sold or (iii) February 26, 2014, which date may be extended by the Placement Agent and the Company in
their joint discretion until March 28, 2014 (either such date, the “Outside Date”). The date on which the Offering expires or is terminated shall be referred to as the “Termination Date.” 

With respect to the Offering, the Company shall provide the Placement Agent, on terms set forth herein, the right to offer all of the Units
being offered. Purchases of Units may be made by the Placement Agent and its officers, directors, employees and affiliates. The Company may, in its sole discretion, accept or reject, in whole or in part, any prospective investment in the Units

 
or allot to any prospective subscriber less than the number of Units that such subscriber desires to purchase; provided, however, that the Placement Agent shall have the right to reject
any prospective investment approved by the Company in its reasonable discretion. Notwithstanding anything to the contrary set forth herein, it is understood that no sale shall be regarded as effective unless and until accepted by the Company. 

The Offering will be made by the Company solely pursuant to the Memorandum, which at all times will be in form and substance reasonably
acceptable to the Company, the Placement Agent and their respective counsel and contain such legends and other information as the Company, the Placement Agent and their respective counsel, may, from time to time, deem necessary and desirable to be
set forth therein. “Memorandum” as used in this Agreement means the Confidential Private Placement Memorandum dated January 27, 2014, inclusive of all annexes, and all amendments, supplements and appendices thereto. 

1. Appointment of Placement Agent. On the basis of the representations and warranties provided herein, and subject to the terms and
conditions set forth herein, the Placement Agent is appointed as exclusive Placement Agent for the Company during the Offering Period to assist the Company in finding qualified subscribers for the Offering. The Placement Agent may offer Units
through other broker-dealers who are FINRA members and may reallow all or a portion of the Agent Compensation (as defined in Section 3(b) below) it receives to such other broker-dealers. On the basis of such representations and warranties and
subject to such terms and conditions, the Placement Agent hereby accepts such appointment and agrees to perform its services hereunder diligently and in good faith and in a professional and businesslike manner and to use its reasonable efforts to
assist the Company in (A) finding subscribers of Units who qualify as “accredited investors,” as such term is defined in Rule 501 of Regulation D, and (B) completing the Offering. The Placement Agent has no obligation to purchase
any of the Units. The engagement of the Placement Agent hereunder shall continue until the Termination Date. 
 2. Representations,
Warranties and Covenants of the Company. Except as set forth in the schedule of exceptions delivered to the Placement Agent on the date hereof (the “Schedule of Exceptions”) or in the Memorandum, the representations and
warranties of the Company contained in this Section 2 are true and correct as of the date of this Agreement and the Company covenants as follows, as applicable. 

(a) The Units will be offered and sold pursuant to the registration exemption provided by Regulation D and Section 4(a)(2) of the Act as
a transaction not involving a public offering and the requirements of any other applicable state securities laws and the respective rules and regulations thereunder in those United States jurisdictions in which the Placement Agent notifies the
Company that the Units are being offered for sale. Neither the Company nor, to the Company’s knowledge, any of its affiliates, or any person acting on its or their behalf (other than the Placement Agent, its affiliates or any person acting on
its behalf, in respect of which no representation is made), has taken, nor will it take, any action that conflicts with the conditions and requirements of, or that would make unavailable with respect to the Offering, the exemption(s) from
registration available pursuant to Rule 506(b) of Regulation D or Section 4(a)(2) of the Act, or knows of any reason why any such exemption would be otherwise 

  
 2 

 
unavailable to it. The Company has not, for a period of six months prior to the commencement of the offering of Units, sold, offered for sale or solicited any offer to buy any of its securities
in a manner that would be integrated with the offer and sale of the Units pursuant to this Agreement and would cause the exemption from registration set forth in Rule 506(b) of Regulation D to become unavailable with respect to the offer and sale of
the Units in the United States pursuant to terms described in the Memorandum. 
 (b) The Memorandum, as supplemented by the Supplemental
Information (as defined in the Memorandum), does not include any untrue statement of a material fact or omit to state any material fact required to be stated in the Memorandum or necessary to make the statements therein, in light of the
circumstances under which they were made, not misleading: provided, however, the foregoing does not apply to any statements or omissions made solely in reliance on and in conformity with written information furnished to the Company by
the Placement Agent specifically for use in the preparation thereof. To the knowledge of the Company, none of the statements, documents, certificates or other items made, prepared or supplied by the Company, including the Memorandum, as supplemented
by the Supplemental Information, with respect to the transactions contemplated hereby contains an untrue statement of a material fact or omits to state a material fact necessary to make the statements contained therein not misleading in light of the
circumstances in which they were made. There is no fact which the Company has not disclosed in the Memorandum, as supplemented by the Supplemental Information, of which the Company is aware that materially adversely affects or that could reasonably
be expected to have a material adverse effect on the (i) assets, liabilities, results of operations, condition (financial or otherwise), business or business prospects of the Company or (ii) ability of the Company to perform its
obligations under this Agreement. Notwithstanding anything to the contrary herein, the Company makes no representation or warranty with respect to any estimates, projections and other forecasts and plans (including the reasonableness of the
assumptions underlying such estimates, projections and other forecasts and plans) that have been delivered or made available to the Placement Agent or its representatives or that are contained in the Memorandum, except that such estimates,
projections and other forecasts and plans have been prepared in good faith on the basis of assumptions stated therein, which assumptions were believed to be reasonable at the time of such preparation. 

(c) The Company is duly organized and validly existing in good standing under the laws of the jurisdiction in which it was formed, and has the
requisite corporate power and authority to own its properties and to carry on its business as now being conducted. The Company is not a party to any joint venture and does not directly or indirectly own or hold capital stock or an equity or similar
interest in any entity. The Company is duly qualified as a foreign entity to do business and is in good standing in every jurisdiction in which its ownership of property or the nature of the business conducted by it makes such qualification
necessary, except to the extent that the failure to be so qualified or be in good standing would not have a Material Adverse Effect. As used in this Agreement, “Material Adverse Effect” means any material adverse effect on the
business, properties, assets, operations, results of operations, condition (financial or otherwise) or prospects of the Company, or on the transactions contemplated by the Transaction Documents (as defined below), or on the authority or ability of
the Company to perform its obligations under the Transaction Documents (as defined below). The Company does not, directly or indirectly, own any capital stock, membership interests or any equity interest in any other person or entity. 

  
 3 

 (d) The Company has all requisite corporate power and authority to conduct its business as
presently conducted and as proposed to be conducted (as described in the Memorandum), to enter into and perform its obligations under this Agreement, the Subscription Agreements substantially in the form of Annex A to the Memorandum (each, a
“Subscription Agreement” and collectively, the “Subscription Agreements”), the Escrow Agreement, the Notes, the Warrants and the Agent Warrants (as defined in Section 3(b) below) and the other agreements
contemplated hereby (collectively, the “Transaction Documents”) and to issue, sell and deliver the Units, the Notes, the Warrants, the securities issuable upon conversion of the Notes (the “Conversion Securities”),
the securities issuable upon exercise of the Warrants (the “Warrant Securities”), the Agent Warrants and the Agent Warrant Securities (as defined in Section 3(b)). All corporate action required to be taken by the Company to
authorize the Company to enter into this Agreement has been taken and to authorize the Company to enter into each of the Transaction Documents has been taken or will be taken prior to the First Closing. This Agreement has been duly authorized,
executed and delivered by the Company and upon due execution and delivery by the Placement Agent, this Agreement constitutes, and each of the other the Transaction Documents, upon due execution and delivery by the Company and the other parties
thereto, if any, will constitute, valid and binding obligations of the Company, enforceable against the Company in accordance with their respective terms (i) except as enforceability may be limited by applicable bankruptcy, insolvency,
reorganization, moratorium or other similar laws now or hereafter in effect related to laws affecting creditors’ rights generally, including the effect of statutory and other laws regarding fraudulent conveyances and preferential transfers, and
except that no representation is made herein regarding the enforceability of the Company’s obligations to provide indemnification and contribution remedies and (ii) subject to the limitations imposed by general equitable principles
(regardless of whether such enforceability is considered in a proceeding at law or in equity). 
 (e) None of the execution and delivery of
or performance by the Company under this Agreement or any of the other Transaction Documents or the consummation of the transactions herein or therein contemplated conflicts with or violates, or will result in the creation or imposition of, any
lien, charge or other encumbrance upon any of the assets of the Company under any agreement or other instrument to which the Company is a party or by which the Company or its assets is bound, or any term of the certificate of incorporation or
by-laws of the Company, or any license, permit, judgment, decree, order, statute, rule or regulation applicable to the Company or any of its assets, except in the case of a conflict, violation, lien, charge or other encumbrance (except with respect
to the Company’s Certificate of Incorporation or By-laws) which would not reasonably be expected to have a Material Adverse Effect. 

(f) The Company has the authorized and outstanding capital stock as set forth under the heading “Description of Our Capital Stock”
in the Memorandum as of the date set forth therein. All outstanding shares of capital stock of the Company are duly authorized, validly issued and outstanding, fully paid and nonassessable. Except as described in the Memorandum: (i) there are
no outstanding options, stock subscription agreements, warrants or other rights permitting or requiring the Company or others to purchase or acquire any shares of capital stock 

  
 4 

 
or other equity securities of the Company or to pay any dividend or make any other distribution in respect thereof; (ii) there are no securities issued or outstanding which are convertible
into or exchangeable for any of the foregoing and there are no contracts, commitments or understandings, whether or not in writing, to issue or grant any such option, warrant, right or convertible or exchangeable security; (iii) no shares of
stock or other securities of the Company are reserved for issuance for any purpose; (iv) there are no voting trusts or other contracts, commitments, understandings, arrangements or restrictions of any kind with respect to the ownership, voting
or transfer of shares of stock or other securities of the Company, including, without limitation, any preemptive rights, rights of first refusal, proxies or similar rights; and (v) no person holds a right to require the Company to register any
securities of the Company under the Act or to participate in any such registration. The capital stock of the Company conforms in all material respects to all statements in relation thereto contained in the Memorandum. All issuances by the Company of
its securities have been, at the times of their issuance, exempt from registration under the Act and any applicable state securities laws. 

(g) Prior to the time of issuance thereof, the Conversion Securities, the Warrant Securities and the Agent Warrant Securities will have been
duly authorized and, when issued and delivered against payment therefor as provided in the Units, the Notes, the Warrants and the Agent Warrants, as applicable, will be validly issued, fully paid and nonassessable. None of the Conversion Securities,
the Warrant Securities or the Agent Warrant Securities are subject to preemptive or similar rights of any stockholder or security holder or an adjustment under the antidilution or exercise rights of any holders of any outstanding shares of capital
stock, options, warrants or other rights to acquire any securities of the Company that have not been waived with respect thereto prior to the issuance of such securities. Immediately prior to the issuance thereof, a sufficient number of authorized
but unissued Conversion Securities, Warrant Securities and Agent Warrant Securities will have been reserved for issuance. 
 (h) The
Company’s financial statements, together with the related notes, if any, included in the Memorandum, present fairly, in all material respects, the financial position of the Company as of the dates specified and the results of operations for the
periods covered thereby. Such financial statements and related notes were prepared substantially in accordance with United States generally accepted accounting principles applied on a consistent basis throughout the periods indicated, except that
the unaudited financial statements omit full notes, and except for normal year-end adjustments. Except as set forth in such financial statements the Company does not have any material liabilities of any kind, whether accrued, absolute or contingent,
or otherwise. The other financial and statistical information with respect to the Company and the pro forma information and related notes included in the Memorandum, if any, present fairly in all material respects the information shown therein on a
basis consistent with the financial statements of the Company included in the Memorandum. 
 (i) Since the date of the Company’s most
recent financial statements contained in the Memorandum (such date, the “Financial Statements Date”), there has been no Material Adverse Effect. Since the Financial Statements Date, the Company has not (i) declared or paid any
dividends, (ii) sold any assets, individually or in the aggregate, in excess of $75,000 outside of the ordinary course of business or (iii) had capital expenditures, individually or in the aggregate, in excess of $75,000. The Company has
not taken any steps to seek protection pursuant to any bankruptcy law nor does the Company have any knowledge or reason to believe that its creditors intend to initiate involuntary bankruptcy proceedings or any actual knowledge of any fact which
would reasonably lead a creditor to do so. 

  
 5 

 (j) The Company has no outstanding Indebtedness (as defined below) in excess of $75,000 except as
described in the Memorandum, and is not in violation of any term of or in default under any contract, agreement or instrument relating to any Indebtedness, except where such violations and defaults would not result, individually or in the aggregate,
in a Material Adverse Effect. For purposes of this Agreement: (i) “Indebtedness” of any Person means without duplication, (A) all indebtedness for borrowed money, (B) all obligations issued, undertaken or assumed as
the deferred purchase price of property or services including (without limitation) “Capital Leases” (as defined under GAAP) (other than trade payables entered into in the ordinary course of business), (C) all reimbursement or payment
obligations with respect to letters of credit, surety bonds and other similar instruments, (D) all obligations evidenced by notes, bonds, debentures or similar instruments, including obligations so evidenced incurred in connection with the
acquisition of property, assets or businesses, (E) all indebtedness created or arising under any conditional sale or other title retention agreement, or incurred as financing, in either case with respect to any property or assets acquired with
the proceeds of such indebtedness (even though the rights and remedies of the seller or bank under such agreement in the event of default are limited to repossession or sale of such property), (F) all monetary obligations under any leasing or
similar arrangement which, in connection with GAAP, consistently applied for the periods covered thereby, is classified as a capital lease, (G) all indebtedness referred to in clauses (A) through (F) above secured by (or for which the
holder of such Indebtedness has an existing right, contingent or otherwise, to be secured by) any mortgage, lien, pledge, charge, security interest or other encumbrance upon or in any property or assets (including accounts and contract rights) owned
by any Person, even though the Person which owns such assets or property has not assumed or become liable for the payment of such indebtedness, and (H) all Contingent Obligations in respect of indebtedness or obligations of others of the kinds
referred to in clauses (A) through (G) above of at least $75,000; (ii) “Contingent Obligation” means, as to any Person, any direct or indirect liability, contingent or otherwise, of that Person with respect to any
indebtedness, lease, dividend or other obligation of another Person if the primary purpose or intent of the Person incurring such liability, or the primary effect thereof, is to provide assurance to the obligee of such liability that such liability
will be paid or discharged, or that any agreements relating thereto will be complied with, or that the holders of such liability will be protected (in whole or in part) against loss with respect thereto; and (iii) “Person”
means an individual, a limited liability company, a partnership, a joint venture, a corporation, a trust, an unincorporated organization and a government or any department or agency thereof. 

(k) The Company has obtained all material licenses, permits and other governmental authorizations necessary to conduct its business as
presently conducted. The Company has not received any written notice of any violation of, or noncompliance with, any federal, state, local or foreign laws, ordinances, regulations and orders (including, without limitation, those relating to
environmental protection, occupational safety and health, securities laws, equal employment opportunity, consumer protection, credit reporting, “truth-in-lending”, and warranties and trade practices) applicable to its business, the
violation of, or noncompliance with, would have an the Material Adverse Effect. 

  
 6 

 (l) The Company owns all right, title and interest in, or possesses adequate and enforceable
rights to use, all patents, patent applications, trademarks, service marks, copyrights, licenses, trade secrets, confidential information, processes and formulations necessary for the conduct of its business as now conducted (collectively, the
“Intangibles”). To the knowledge of the Company, the Company has not infringed upon the rights of others with respect to the Intangibles and the Company has not received written notice that it has or may have infringed or is
infringing upon the rights of others with respect to the Intangibles, or any written notice of conflict with the asserted rights of others with respect to the Intangibles. To the knowledge of the Company, no others have infringed upon the rights of
the Company with respect to the Intangibles. None of the Intangibles have expired or terminated, or are scheduled to expire or terminate, within three years from the date of this Agreement. 

(m) The Company is not a party to any collective bargaining agreement and does not employ any member of a union. No executive officer of the
Company (as defined in Rule 501(f) under the Act) has notified the Company that such officer intends to leave the Company or otherwise terminate such officer’s employment with the Company. To the Company’s knowledge, no executive officer
of the Company is in violation of any material term of any employment contract, confidentiality, disclosure or proprietary information agreement, non-competition agreement, or any other contract or agreement or any restrictive covenant. The Company
is in compliance with all federal, state, local and foreign laws and regulations respecting labor, employment and employment practices and benefits, terms and conditions of employment and wages and hours, except where failure to be in compliance
would not, either individually or in the aggregate, reasonably be expected to result in a Material Adverse Effect. 
 (n) No consent,
authorization or filing of or with any court or governmental authority is required in connection with the issuance or the consummation of the transactions contemplated herein or in the other Transaction Documents, except for required filings with
the SEC and the applicable state securities commissions relating specifically to the Offering (all of which filings will be duly made), other than those which are required to be made after the First Closing (all of which will be duly made on a
timely basis). 
 (o) Subsequent to the Financial Statements Date, the Company has operated its business in the ordinary course and there
has been no: (i) the Material Adverse Effect; (ii) transaction otherwise than in the ordinary course of business consistent with past practice; (iii) issuance of any securities (debt or equity) or any rights to acquire any such
securities other than pursuant to equity incentive plans approved by its Board of Directors; (iv) damage, loss or destruction, whether or not covered by insurance, with respect to any asset or property of the Company; or (v) agreement to
permit any of the foregoing. 
 (p) There are no actions, suits, claims, hearings or proceedings pending before any court or governmental
authority or, to the knowledge of the Company, threatened, against the Company, or involving its assets or any of its officers or directors (in their capacity as such) which, if determined adversely to the Company or such officer or director, could
reasonably be expected to have an the Material Adverse Effect. 

  
 7 

 (q) The Company is not: (i) in violation of its Certificate of Incorporation or By-laws;
(ii) in default of any indenture, mortgage, deed of trust, note or other agreement or instrument to which it is a party or by which it is bound or to which any of its assets are subject, the default of which could reasonably be expected to have
an the Material Adverse Effect; (iii) in violation of any statute, rule or regulation applicable to it, the violation of which would have an the Material Adverse Effect; or (iv) in violation of any judgment, decree or order of any court or
governmental body, which violation or violations individually, or in the aggregate, could reasonably be expected to have an the Material Adverse Effect. 

(r) Except as described in the Memorandum, as of the date of this Agreement, no current or former stockholder, director, officer or employee
of the Company, nor, to the knowledge of the Company, any affiliate of any such person is presently, directly or indirectly through his affiliation with any other person or entity, a party to any loan from the Company or any other transaction (other
than as an employee) with the Company providing for the furnishing of services by, or rental of any personal property from, or otherwise requiring cash payments to any such person. 

(s) The Company has filed, on a timely basis, each federal, state, local and foreign tax return, report and declarations that were required to
be filed, or has requested an extension therefor and has paid all taxes and all related assessments, charges, penalties and interest to the extent that the same have become due. There are no unpaid taxes in any material amount claimed to be due by
the taxing authority of any jurisdiction, and the officers of the Company know of no basis for any such claim. The Company has not executed a waiver with respect to the statute of limitations relating to the assessment or collection of any foreign,
federal, state or local tax. To the Company’ knowledge, none of the Company’s tax returns is presently being audited by any taxing authority. No liens have been filed and no claims are being asserted by or against the Company with respect
to any taxes (other than liens for taxes not yet due and payable). The Company has not received written notice of assessment or proposed assessment of any taxes claimed to be owed by it or any other Person on its behalf. The Company is not a party
to any tax sharing or tax indemnity agreement or any other agreement of a similar nature that remains in effect. The Company has complied in all material respects with all applicable legal requirements relating to the payment and withholding of
taxes and, within the time and in the manner prescribed by law, has withheld from wages, fees and other payments and paid over to the proper governmental or regulatory authorities all amounts required. 

(t) Neither the Company nor any director, officer, agent, employee or other Person acting on behalf of the Company has, in the course of its
actions for, or on behalf of, the Company (i) used any corporate funds for any unlawful contribution, gift, entertainment or other unlawful expenses relating to political activity; (ii) made any direct or indirect unlawful payment to any
foreign or domestic government official or employee from corporate funds; (iii) violated or is in violation of any provision of the U.S. Foreign Corrupt Practices Act of 1977, as amended; or (iv) made any unlawful bribe, rebate, payoff,
influence payment, kickback or other unlawful payment to any foreign or domestic government official or employee. 
 (u) The Company is not
obligated to pay, and has not obligated the Placement Agent to pay, a finder’s or origination fee in connection with the Offering (other than to the 

  
 8 

 
Placement Agent), and hereby agrees to indemnify the Placement Agent from any such claim made by any other person as more fully set forth in Section 8 hereof. The Company has not offered for
sale or solicited offers to purchase the Units except for negotiations with the Placement Agent 
 (v) Neither the sale of the Units by the
Company nor its use of the proceeds thereof will violate the Trading with the Enemy Act, as amended, or any of the foreign assets control regulations of the United States Treasury Department (31 CFR, Subtitle B, Chapter V, as amended) or any
enabling legislation or executive order relating thereto. Without limiting the foregoing, the Company is not (a) a person whose property or interests in property are blocked pursuant to Section 1 of Executive Order 13224 of
September 23, 2001 Blocking Property and Prohibiting Transactions with Persons Who Commit, Threaten to Commit, or Support Terrorism (66 Fed. Reg. 49079 (2001)) or (b) a person who engages in any dealings or transactions, or be
otherwise associated, with any such person. The Company is in compliance, in all material respects, with the USA Patriot Act of 2001 (signed into law October 26, 2001). 

(w) Until the Termination Date, the Company will not issue any press release, grant any interview, or otherwise communicate with the media in
any manner whatsoever with respect to the Offering without the Placement Agent’s prior written consent, which consent will not unreasonably be withheld or delayed. 

(x) The Company is in the process of establishing internal accounting controls sufficient to provide reasonable assurances that
(i) transactions are executed in accordance with management’s general or specific authorization; (ii) transactions are recorded as necessary to permit preparation of financial statements in conformity with generally accepted
accounting principles and to maintain accountability for assets; (iii) access to assets is permitted only in accordance with management’s general or specific authorization; and (iv) the recorded accountability for assets is compared
with existing assets at reasonable intervals and appropriate action is taken with respect to any differences. 
 (y) Neither the Company nor
any of Company Related Persons (as defined below) are subject to any of the disqualifications set forth in Rule 506(d) of Regulation D. The Memorandum contains a true and complete description of the matters required to be disclosed with respect to
the Company and the Company Related Persons pursuant to the disclosure requirements of Rule 506(e) of Regulation D, to the extent applicable. As used herein, “Company Related Persons” means any predecessor of the Company, any
affiliated issuer, any director, executive officer, other officer of the Company participating in the Offering, any general partner or managing member of the Company, any beneficial owner of 20% or more of the Company’s outstanding voting
equity securities, calculated on the basis of voting power, and any “promoter” (as defined in Rule 405 under the Act) connected with the Company in any capacity. 

2A. Representations, Warranties and Covenants of Placement Agent. The Placement Agent hereby represents and warrants to the Company
that the following representations and warranties are true and correct as of the date of this Agreement: 

  
 9 

 (a) The Placement Agent is a corporation duly organized, validly existing and in good standing
under the laws of the State of New York and has all requisite corporate power and authority to enter into this Agreement and to carry out and perform its obligations under the terms of this Agreement. 

(b) This Agreement has been duly authorized, executed and delivered by the Placement Agent, and upon due execution and delivery by the
Company, this Agreement will constitute, and each of the Transaction Documents to which Placement Agent is a party, upon due execution and delivery by the Placement Agent and all other parties thereto, will constitute, valid and binding obligations
of the Placement Agent enforceable against it in accordance with their respective terms, (i) except as enforceability may be limited by applicable bankruptcy, insolvency, reorganization, moratorium or other similar laws now or hereafter in
effect related to laws affecting creditors’ rights generally, including the effect of statutory and other laws regarding fraudulent conveyances and preferential transfers, and except that no representation is made herein regarding the
enforceability of the Placement Agent’s obligations to provide indemnification and contribution remedies and (ii) subject to the limitations imposed by general equitable principles (regardless of whether such enforceability is considered
in a proceeding at law or in equity). 
 (c) The Placement Agent is a member of FINRA and is registered as a broker-dealer under the
Securities Exchange Act of 1934, as amended (the “Exchange Act”), and under the securities acts of each state into which it is making offers or sales of the Units. None of the Placement Agent or its affiliates, or any person acting
on behalf of the foregoing (other than the Company, its or their affiliates or any person acting on its or their behalf, in respect of which no representation is made) has taken nor will it take any action that conflicts with the conditions and
requirements of, or that would make unavailable with respect to the Offering, the exemption(s) from registration available pursuant to Rule 506(b) of Regulation D or Section 4(a)(2) of the Act, or knows of any reason why any such exemption
would be otherwise unavailable to it. 
 (d) Neither the Placement Agent nor any of Placement Agent Related Persons (as defined below) are
subject to any of the disqualifications set forth in Rule 506(d) of Regulation D. The Memorandum contains a true and complete description of the matters required to be disclosed with respect to the Placement Agent and the Placement Agent Related
Persons pursuant to the disclosure requirements of Rule 506(e) of Regulation D, to the extent applicable. As used herein, “Placement Agent Related Persons” means any person associated with the Placement Agent that has been or will
be paid (directly or indirectly) remuneration for solicitation of investors in connection with the sale of the Units; any general partner or managing member of the Placement Agent; or any director, executive officer or other officer of the Placement
Agent participating in the offering of the Units. 
 3. Placement Agent Compensation. 

(a) In connection with the Offering, the Company will pay to the Placement Agent at each Closing (i) a cash fee (the “Agent Cash
Fee”) equal to ten percent (10%) of the gross proceeds from the sale of the Units consummated at such Closing, provided, that the Agent Cash Fee shall be three percent (3%) for Units sold to current investors of the
Company, and (ii)

  
 10 

 
a non-accountable expense allowance equal to 2% of the gross proceeds from the sale of the Units consummated at such Closing up to a maximum aggregate amount of $100,000 for all Closings (the
“Agent Expense Allowance”). The Placement Agent will not bear any of the Company’s legal, accounting, printing or other expenses in connection with any transaction contemplated hereby. 

(b) As additional compensation, at the Final Closing the Company will issue to the Placement Agent (or its designee(s)) for nominal
consideration, warrants to purchase securities of the Company as described in the Memorandum (the “Agent Warrants” the Agent Cash Fee and Agent Warrants are sometimes referred to herein collectively as “Agent
Compensation”). 
 (c) The Company shall also pay to the Placement Agent the Agent’s Cash Fee and Agent Warrants if, during a
period of twelve (12) months following the earlier of the Final Closing of the Offering or the Termination Date (the “Tail Period”) any party contacted by the Placement Agent as a potential subscriber in the Offering during the
Offering Period, or affiliate of such party (an “Aegis Investor”), purchases newly issued securities from the Company in an offering not registered under the Act. Within five (5) Business Days following the end of the Offering
Period, the Placement Agent will deliver to the Company a list of Aegis Investors which list shall be final and binding on the parties unless the Company shall reasonably object to such list within two (2) Business Days of its receipt of such
list. In the event of any dispute, the parties shall use their respective good faith efforts to resolve such dispute as promptly as practicable. The Agent’s Cash Fee and Agent Warrants will be calculated according to the percentages set forth
in Sections 3(a) and (b) respectively, of this Agreement, based on the amount of any such investment. 
 4. Subscription and Closing
Procedures. 
 (a) The Company has caused, or shall cause, to be delivered to the Placement Agent copies of the Memorandum and has
consented, and hereby consents, to the use of such copies for the purposes permitted by the Act and applicable securities laws and in accordance with the terms and conditions of this Agreement, and hereby authorizes the Placement Agent and its
agents and employees to use the Memorandum in connection with the offering of the Units until the Termination Date, and no person or entity is or will be authorized to give any information or make any representations other than those contained in
the Memorandum or to use any offering materials other than those contained in the Memorandum in connection with the Offering. 
 (b) During
the Offering Period, the Company shall make available to the Placement Agent and its representatives such information as may be reasonably requested in making a reasonable investigation of the Company and its affairs and shall provide reasonable
access to such employees during normal business hours as shall be reasonably requested by the Placement Agent. 
 (c) Each prospective
purchaser will be required to (i) complete and execute a Subscription Agreement and to deliver the same to the Placement Agent at the Placement 

  
 11 

 
Agent’s offices at the address set forth in Section 12 hereof, and (ii) to wire the full amount of the purchase price for the number of Units desired to be purchased, subject to
the Escrow Agent’s right to accept a check in lieu of a wire transfer, to Signature Bank, as escrow agent (the “Escrow Agent”), in accordance with the terms and conditions of the Subscription Agreements. 

(d) The Escrow Agent will deposit all funds for subscriptions received from the Offering into a non-interest bearing escrow account (the
“Escrow Account”). All such funds for subscriptions will be held in the Escrow Account pursuant to the terms of an escrow agreement among the Company, the Placement Agent and the Escrow Agent (the “Escrow
Agreement”). The Company will pay all reasonable fees related to the establishment and maintenance of the Escrow Account. The Placement Agent shall, in a timely fashion, deliver to the Company an executed copy of each Subscription Agreement
received by the Placement Agent. The Company will either accept or reject, in whole or in part, for any or no reason, each Subscription Agreement in a timely fashion and at each Closing the Company will countersign each Subscription Agreement
accepted by the Company and provide duplicate copies of such documents to the Placement Agent for distribution to the subscribers. The Placement Agent, on the Company’s behalf and at its direction, will promptly return to subscribers
incomplete, improperly completed, improperly executed and rejected Subscription Agreements and give written notice thereof to the Company upon such return. 

(e) If subscriptions have been accepted prior to the Termination Date, the funds therefor have been collected by the Escrow Agent, and all of
the conditions set forth elsewhere in this Agreement are fulfilled, a closing shall be held promptly with respect to Units sold (the “First Closing”). Thereafter remaining Units will continue to be offered and may be sold until the
Termination Date and additional closings (each a “Closing”, and the date on which any Closing occurs, a “Closing Date”) may from time to time be conducted at times mutually agreed to between the Placement Agent and
the Company with respect to additional Units sold, with the final closing (“Final Closing”) to occur within 10 days of the earlier of the Outside Date and the date on which all of the Units have been fully subscribed for, all in
accordance with the procedures set forth herein. Delivery of payment of the net purchase price for the accepted subscriptions for Units from funds held in the Escrow Account will be made to the Company at each Closing against delivery of the Notes
and Warrants by the Company to the Purchasers. Executed Notes, Warrants and the Placement Agent Warrants will be in such authorized denominations and will be registered in such names as the Placement Agent may request and will be made available to
the Placement Agent for checking and packaging at the Placement Agent’s office at each Closing or within three (3) business days following a Closing; provided, however, that, unless a later date shall be requested by the Placement Agent,
the Agent Warrants will be delivered upon the earlier of (i) the Final Closing and (ii) the end of the Offering Period. 
 (f) If
no subscriptions have been accepted by the Company on or before the Termination Date for any reason, the Offering will be terminated, no Units will be sold, and the Escrow Agent will, at the request of the Placement Agent, cause all monies received
from subscribers for the Units to be promptly returned to such subscribers without interest, penalty, expense or deduction. 

  
 12 

 5. Further Covenants. The Company hereby covenants and agrees that: 

(a) Except upon prior written notice to the Placement Agent, the Company shall not, at any time during the Offering Period, knowingly take any
action which would cause any of the representations and warranties made by it in this Agreement not to be complete and correct in all material respects on and as of each Closing Date with the same force and effect as if such representations and
warranties had been made on and as of each such date (except to the extent any representation or warranty relates to an earlier date). 

(b) If, at any time during the Offering Period, any event shall occur that causes a Material Adverse Effect as a result of which it becomes
necessary to amend or supplement the Memorandum so that the representations and warranties herein remain true and correct in all material respects, or in case it shall be necessary to amend or supplement the Memorandum to comply with applicable law,
the Company will promptly notify the Placement Agent and shall, at its sole cost, prepare and furnish to the Placement Agent copies of appropriate amendments and/or supplements in such quantities as the Placement Agent may reasonably request. The
Company will not at any time during the Offering Period prepare or use any amendment or supplement to the Memorandum of which the Placement Agent will not previously have been advised and furnished with a copy, or which is not in compliance in all
material respects with the Act and other applicable securities laws. As soon as the Company is advised thereof, the Company will advise the Placement Agent and its counsel, and confirm the advice in writing, of any order preventing or suspending the
use of the Memorandum, or the suspension of any exemption for such qualification or registration thereof for offering in any jurisdiction, or of the institution or threatened institution of any proceedings for any of such purposes, and the Company
and will use its best efforts to prevent the issuance of any such order and, if issued, to obtain as soon as reasonably possible the lifting thereof. 

(c) The Company shall comply with the Act and the rules and regulations thereunder, all applicable state securities laws and the rules and
regulations thereunder in the states in which the Units are qualified or registered for sale or exempt from such qualification or registration, so as to permit the continuance of the sales of the Units, and will file or cause to be filed with the
SEC, and shall promptly thereafter forward or cause to be forwarded to the Placement Agent, any and all reports on Form D as are required. 

(d) The Company shall use best efforts to qualify the Units for sale under the securities laws of such jurisdictions in the United States as
may be mutually agreed to by the Company and the Placement Agent, and the Company will make or cause to be made such applications and furnish information as may be required for such purposes, provided that the Company will not be required to qualify
as a foreign corporation in any jurisdiction or execute a general consent to service of process. The Company will, from time to time, prepare and file such statements and reports as are or may be required to continue such qualifications in effect
for so long a period as the Placement Agent may reasonably request with respect to the Offering. 
 (e) The Company shall place a legend on
the instruments representing the Notes, the Warrants and the Agent Warrants that the securities evidenced thereby have not been registered under the Act or applicable state securities laws, setting forth or referring to the applicable restrictions
on transferability and sale of such securities under the Act and applicable state laws. 

  
 13 

 (f) The Company shall apply the net proceeds from the sale of the Units for the purposes
substantially as described under the “Use of Proceeds” section of the Memorandum. Except as set forth in the Memorandum, the Company shall not use any of the net proceeds of the Offering to repay indebtedness to officers (other than
accrued salaries incurred in the ordinary course of business), directors or stockholders of the Company. 
 (g) During the Offering Period,
the Company shall afford each prospective purchaser of Units the opportunity to ask questions of and receive answers from an officer of the Company concerning the terms and conditions of the Offering and the opportunity to obtain such other
additional information necessary to verify the accuracy of the Memorandum to the extent the Company possesses such information or can acquire it without unreasonable expense. 

(h) Except with the prior written consent of the Placement Agent, which consent shall not be unreasonably withheld or delayed, the Company
shall not, at any time during the Offering Period, except as contemplated by the Memorandum (i) engage in or commit to engage in any transaction outside the ordinary course of business as described in the Memorandum, (ii) issue, agree to
issue or set aside for issuance any securities (debt or equity) or any rights to acquire any such securities, (iii) incur, outside the ordinary course of business, any material indebtedness, (iv) dispose of any material assets,
(v) make any material acquisition or (vi) change its business or operations. 
 (i) The Company shall pay all reasonable expenses
incurred by or on behalf of the Company in connection with the preparation and printing of all necessary offering documents and instruments related to the Offering and the issuance of the Notes, the Warrants and the Agent Warrants and will also pay
the Company’s expenses for accounting fees, legal fees and other costs involved with the Offering. The Company will provide at its own expense such quantities of the Memorandum and other documents and instruments relating to the Offering as the
Placement Agent may reasonably request. All Blue Sky filings shall be prepared by the Company’s counsel at the Company’s expense. 

6. Conditions of Placement Agent’s Obligations. The obligations of the Placement Agent hereunder to effect a Closing are subject
to the fulfillment, at or before each Closing, of the following additional conditions: 
 (a) Each of the representations and warranties
made by the Company qualified as to materiality shall be true and correct at all times prior to and on each Closing Date, except to the extent any such representation or warranty expressly speaks as of an earlier date, in which case such
representation or warranty shall be true and correct as of such earlier date, and the representations and warranties made by the Company not qualified as to materiality shall be true and correct in all material respects at all times prior to and on
each Closing Date, except to the extent any such representation or warranty expressly speaks as of an earlier date, in which case such representation or warranty shall be true and correct in all material respects as of such earlier date. 

  
 14 

 (b) The Company shall have performed and complied in all material respects with all agreements,
covenants and conditions required to be performed and complied with by it in this Agreement at or before the Closing. 
 (c) No order
suspending the use of the Memorandum or enjoining the Offering or sale of the Units shall have been issued, and no proceedings for that purpose or a similar purpose shall have been initiated or pending, or, to the best of the Company’s
knowledge, be contemplated or threatened. 
 (d) The Placement Agent shall have received a certificate of the Chief Executive Officer of the
Company, dated as of the Closing Date, certifying, as to the fulfillment of the conditions set forth in subparagraphs (a), (b) and (c) above. 

(e) The Company shall have delivered to the Placement Agent: (i) a certified charter document and good standing certificate, each dated
as of a date within 10 days prior to the Closing Date from the secretary of state of Delaware; and (ii) resolutions of the Company’s Board of Directors approving this Agreement and the transactions and agreements contemplated by this
Agreement, certified by the Chief Executive Officer of the Company. 
 (f) At each Closing, the Company shall pay and/or issue to the
Placement Agent the Agent Compensation and Agent Expense Allowance earned in such Closing; provided, however, that the Company shall be required to issue the Agent Warrants only pursuant to Section 4(e) hereof. 

(g) The Company shall deliver to the Placement Agent a signed opinion of Cooley LLP, counsel to the Company, dated as of the Closing Date, in
form and substance reasonably acceptable to the Placement Agent. 
 (h) All proceedings taken at or prior to the Closing in connection with
the authorization, issuance and sale of the Notes, the Warrants and the Agent Warrants will be reasonably satisfactory in form and substance to the Placement Agent and its counsel, and such counsel shall have been furnished with all such documents,
certificates and opinions as it may reasonably request upon reasonable prior notice in connection with the transactions contemplated hereby. 

7. Conditions of the Company’s Obligations. The obligations of the Company hereunder to effect a Closing are subject to the
fulfillment, at or before each Closing, of the following additional conditions: 
  

	 	(a)	Each of the representations and warranties made by Placement Agent herein are true and correct as of each Closing Date. 

  

	 	(b)	The Company shall have received a certificate of the Placement Agent, dated as of the Closing Date, certifying as to the fulfillment of the condition set forth in subparagraph (a) above. 

  
 15 

 8. Indemnification. 

(a) The Company will: (i) indemnify and hold harmless the Placement Agent, its agents and their respective officers, directors,
employees, selected dealers and each person, if any, who controls the Placement Agent within the meaning of Section 15 of the Act or Section 20(a) of the Exchange Act and such selected dealers (each an “Indemnitee” or a
“Placement Agent Party”) against, and pay or reimburse each Indemnitee for, any and all losses, claims, damages, liabilities or expenses whatsoever (or actions or proceedings or investigations in respect thereof), joint or several
(which will, for all purposes of this Agreement, include, but not be limited to, all reasonable costs of defense and investigation and all reasonable attorneys’ fees, including appeals), to which any Indemnitee may become subject (x) under
the Act or otherwise, in connection with the offer and sale of the Units and (y) as a result of the breach of any representation, warranty or covenant made by the Company herein, regardless of whether such losses, claims, damages, liabilities
or expenses shall result from any claim by any Indemnitee or by any third party; and (ii) reimburse each Indemnitee for any legal or other expenses reasonably incurred in connection with investigating or defending against any such loss, claim,
action, proceeding or investigation; provided, however, that the Company will not be liable in any such case to the extent that any such claim, damage or liability is finally judicially determined to have resulted
exclusively from (A) an untrue statement or alleged untrue statement of a material fact made in the Memorandum, or an omission or alleged omission to state therein a material fact required to be stated therein or necessary to make the
statements therein not misleading, made solely in reliance upon and in conformity with written information furnished to the Company by the Placement Agent or any Placement Agent Party specifically for use in the Memorandum, (B) any violations
by the Placement Agent or any Placement Agent Party of the Act or state securities laws which does not result from a violation thereof by the Company or any of its affiliates, or (C) any willful misconduct or gross negligence by the Placement
Agent or any Placement Agent Party. In addition to the foregoing agreement to indemnify and reimburse, the Company will indemnify and hold harmless each Indemnitee against any and all losses, claims, damages, liabilities or expenses whatsoever (or
actions or proceedings or investigations in respect thereof), joint or several (which shall, for all purposes of this Agreement, include, but not be limited to, all reasonable costs of defense and investigation and all reasonable attorneys’
fees, including appeals) to which any Indemnitee may become subject insofar as such costs, expenses, losses, claims, damages or liabilities arise out of or are based upon the claim of any person or entity that he or it is entitled to broker’s
or finder’s fees from any Indemnitee in connection with the Offering, other than fees due to the Placement Agent. The foregoing indemnity agreements will be in addition to any liability the Company may otherwise have. 

(b) The Placement Agent will indemnify and hold harmless the Company, its officers, directors, and each person, if any, who controls the
Company within the meaning of Section 15 of the Act or Section 20(a) of the Exchange Act against, and pay or reimburse any such person for, any and all losses, claims, damages, liabilities or expenses whatsoever (or actions, proceedings or
investigations in respect thereof) to which the Company or any such person may become subject under the Act or otherwise, whether such losses, claims, damages, liabilities or expenses shall result from any claim of the Company or any such person who
controls the Company within the meaning of the Act or by any third party, but only to the extent 

  
 16 

 
that such losses, claims, damages or liabilities are based upon any untrue statement or alleged untrue statement of any material fact contained in the Memorandum made in reliance upon and in
conformity with information contained in the Memorandum relating to the Placement Agent, or an omission or alleged omission to state therein a material fact required to be stated therein or necessary to make the statements therein not misleading, in
either case, if made or omitted in reliance upon and in conformity with written information furnished to the Company by the Placement Agent, specifically for use in the preparation thereof. The Placement Agent will reimburse the Company or any such
person for any legal or other expenses reasonably incurred in connection with investigating or defending against any such loss, claim, damage, liability or action, proceeding or investigation to which such indemnity obligation applies. The foregoing
indemnity agreements are in addition to any liability which the Placement Agent may otherwise have. 
 (c) Promptly after receipt by an
indemnified party under this Section 8 of notice of the commencement of any action, claim, proceeding or investigation (the “Action”), such indemnified party, if a claim in respect thereof is to be made against the indemnifying
party under this Section 8, will notify the indemnifying party of the commencement thereof, but the omission to so notify the indemnifying party will not relieve it from any liability that it may have to any indemnified party under this
Section 8 unless the indemnifying party has been substantially prejudiced by such omission. The indemnifying party will be entitled to participate in and, to the extent that it may wish, jointly with any other indemnifying party, to assume the
defense thereof subject to the provisions herein stated, with counsel reasonably satisfactory to such indemnified party. The indemnified party will have the right to employ separate counsel in any such Action and to participate in the defense
thereof, but the fees and expenses of such counsel will not be at the expense of the indemnifying party if the indemnifying party has assumed the defense of the Action with counsel reasonably satisfactory to the indemnified party, provided,
however, that if the indemnified party shall be requested by the indemnifying party to participate in the defense thereof or shall have concluded in good faith and specifically notified the indemnifying party either that there may be specific
defenses available to it that are different from or additional to those available to the indemnifying party or that such Action involves or could have a material adverse effect upon it with respect to matters beyond the scope of the indemnity
agreements contained in this Agreement, then the counsel representing it, to the extent made necessary by such defenses, shall have the right to direct such defenses of such Action on its behalf and in such case the reasonable fees and expenses of
such counsel in connection with any such participation or defenses shall be paid by the indemnifying party. No settlement of any Action against an indemnified party will be made without the consent of the indemnifying party and the indemnified
party, which consent shall not be unreasonably withheld or delayed in light of all factors of importance to such party, and no indemnifying party shall be liable to indemnify any person for any settlement of any such claim effected without such
indemnifying party’s consent. 
 9. Contribution. To provide for just and equitable contribution, if: (i) an indemnified
party makes a claim for indemnification pursuant to Section 8 hereof and it is finally determined, by a judgment, order or decree not subject to further appeal that such claims for indemnification may not be enforced, even though this Agreement
expressly provides for indemnification in such case; or (ii) any indemnified or indemnifying party seeks contribution under the Act, the 

  
 17 

 
Exchange Act, or otherwise, then each indemnifying party shall contribute to such amount paid or payable by such indemnified party in such proportion as is appropriate to reflect not only such
relative benefits but also the relative fault of the Company on the one hand and the Placement Agent on the other in connection with the statements or omissions which resulted in such losses, claims, damages, liabilities or expenses (or actions in
respect thereof), as well as any other relevant equitable considerations. The relative benefits received by the Company on the one hand and the Placement Agent on the other shall be deemed to be in the same proportion as the total net proceeds from
the Offering (before deducting expenses) received by the Company bear to the total Agent Cash Fees received by the Placement Agent. The relative fault, in the case of an untrue statement, alleged untrue statement, omission or alleged omission will
be determined by, among other things, whether such statement, alleged statement, omission or alleged omission relates to information supplied by the Company or by the Placement Agent, and the parties’ relative intent, knowledge, access to
information and opportunity to correct or prevent such statement, alleged statement, omission or alleged omission. The Company and the Placement Agent agree that it would be unjust and inequitable if the respective obligations of the Company and the
Placement Agent for contribution were determined by pro rata allocation of the aggregate losses, liabilities, claims, damages and expenses or by any other method or allocation that does not reflect the equitable considerations referred to in
this Section 9. No person guilty of a fraudulent misrepresentation (within the meaning of Section 11(f) of the Act) will be entitled to contribution from any person who is not guilty of such fraudulent misrepresentation. For purposes of
this Section 9, each person, if any, who controls the Placement Agent within the meaning of the Act will have the same rights to contribution as the Placement Agent, and each person, if any, who controls the Company within the meaning of the
Act will have the same rights to contribution as the Company, subject in each case to the provisions of this Section 9. Anything in this Section 9 to the contrary notwithstanding, no party will be liable for contribution with respect to
the settlement of any claim or action effected without its written consent. This Section 9 is intended to supersede, to the extent permitted by law, any right to contribution under the Act, the Exchange Act or otherwise available. 

10. Termination. 
 (a)
The Offering may be terminated by the Placement Agent at any time prior to the expiration of the Offering Period in the event that: (i) any of the representations or warranties of the Company contained herein or in the Memorandum shall prove to
have been false or misleading in any material respect when actually made; (ii) the Company shall have failed to perform any of its material obligations hereunder or under any other Transaction Document; (iii) there shall occur any event
that could reasonably be expected to result in a Material Adverse Effect; or (iv) the Placement Agent determines that it is reasonably likely that any of the conditions to Closing set forth herein will not, or cannot, be satisfied. In the event
of any such termination by the Placement Agent pursuant to clauses (i), (ii) or (iii) of this Section 10(a) (with respect to clause (iii) only, due to an event within the control of the Company), the Placement Agent shall be
entitled to receive from the Company, within five (5) business days of the Termination Date, an amount equal to the sum of $100,000 (the “Termination Amount”). In the event of a termination by the Placement Agent under
Section 10(a)(iv), the Placement Agent shall not be entitled to any further compensation pursuant to these termination provisions. 

  
 18 

 (b) This Offering may be terminated by the Company at any time prior to the expiration of the
Offering Period. In the event of any such termination pursuant to this Section 10(b), the Placement Agent shall not be entitled to any further compensation pursuant to these termination provisions and Section 3(c) shall also terminate.

 (c) In the event the Company unilaterally decides for any reason (other than pursuant to Section 10(b) above or Section 10(d)
below) to terminate the Offering at any time prior to the First Closing, the Placement Agent shall be entitled to receive from the Company the Termination Amount. 

(d) This Offering may be terminated upon mutual agreement of the Company and the Placement Agent at any time prior to the expiration of the
Offering Period. In addition, upon the expiration of the Offering Period, the Offering shall terminate without any further action of the parties hereto. If the Offering is terminated pursuant to this Section 10(d), then in cases in which no
Closing had been theretofore consummated, each party shall pay its own respective expenses.  
 (e) Before any termination by the
Placement Agent under Section 10(a) or by the Company under Section 10(b) shall become effective, the terminating party shall give written notice to the other party of its intention to terminate the Offering (the “Termination
Notice”). The Termination Notice shall specify the grounds for the proposed termination. If the specified grounds for termination, or their resulting adverse effect on the transactions contemplated hereby, are curable, then the other party
shall have ten (10) days from the Termination Notice within which to remove such grounds or to eliminate all of their material adverse effects on the transactions contemplated hereby; otherwise, the Offering shall terminate. 

(f) Upon any termination pursuant to this Section 10, the Placement Agent and the Company will instruct Escrow Agent to cause all monies
received with respect to the subscriptions for Units not accepted by the Company to be promptly returned to such subscribers in accordance with the terms and conditions of the Escrow Agreement. 

11. Survival. 
 (a) The
obligations of the parties to pay any costs and expenses hereunder and to provide indemnification and contribution as provided herein shall survive any termination hereunder. In addition, except as otherwise provided herein, the provisions of
Sections 3(c), and 8 through 16 shall survive the sale of the Units or any termination of the Offering hereunder. 
 (b) The respective
representations, warranties and other statements of the Company and the Placement Agent set forth in or made pursuant to this Agreement will remain in full force and effect, regardless of any investigation made by or on behalf of, and regardless of
any access to information by, the Company or the Placement Agent, or any of their officers or directors or any controlling person thereof, and will survive the sale of the Units or any termination of the Offering hereunder for a period of three
(3) years from the earlier to occur of the Final Closing or the termination of the Offering. 

  
 19 

 12. Notices. Any notice or other communications required to be given hereunder shall be in
writing and shall be deemed effectively given: (a) upon personal delivery to the party notified; (b) or when sent by email or facsimile transmission if sent during normal business hours of the recipient, if not, then on the next business
day; (c) five days after having been sent by registered or certified mail, return receipt requested, postage prepaid; or (d) one day after deposit with a nationally recognized overnight courier, specifying next day delivery, with written
verification of receipt. All communications shall be sent to the parties at their respective address, email or facsimile number as follows: if sent to the Placement Agent, notice will be mailed, delivered, emailed or faxed and confirmed to Aegis
Capital Corp., 810 Seventh Ave, 11th Floor, New York, NY 10019, Attention: Adam K. Stern, email address adam@sternaegis.com, fax number (646) 390-9122, with a copy (which shall not constitute notice) to: Lowenstein Sandler LLP, 1251
Avenue of the Americas, New York, NY 10020, Attn: John D. Hogoboom, email address jhogoboom@lowenstein.com, fax number (973) 597-2383, and if sent to the Company, will be mailed, delivered or telefaxed and confirmed to GlobeImmune, Inc.,
1450 Infinite Drive, Louisville, CO 80027, Attn: Timothy C. Rodell, M.D., Chief Executive Officer and President, email address tcrodell@globeimmune.com, fax number (303) 625-2810, with a copy (which shall not constitute notice) to:
Cooley LLP, 280 Interlocken Crescent, Suite 900, Broomfield, CO 80021, Attn: Brent D. Fassett, email address bfassett@cooley.com, fax number (720) 566-4099. 

13. Governing Law, Jurisdiction. This Agreement shall be deemed to have been made and delivered in New York City and shall be governed
as to validity, interpretation, construction, affect and in all other respects by the internal laws of the State of New York. THE PARTIES AGREE THAT ANY DISPUTE, CLAIM OR CONTROVERSY DIRECTLY OR INDIRECTLY RELATING TO OR ARISING OUT OF THIS
AGREEMENT, THE TERMINATION OR VALIDITY HEREOF, ANY ALLEGED BREACH OF THIS AGREEMENT OR THE ENGAGEMENT CONTEMPLATED HEREBY (ANY OF THE FOREGOING, A “CLAIM”) SHALL BE SUBMITTED TO THE JUDICIAL ARBITRATION AND MEDIATION SERVICES, INC
(“JAMS”), OR ITS SUCCESSOR, IN NEW YORK, FOR FINAL AND BINDING ARBITRATION IN FRONT OF A PANEL OF THREE ARBITRATORS WITH JAMS IN NEW YORK, NEW YORK UNDER THE JAMS COMPREHENSIVE ARBITRATION RULES AND PROCEDURES (WITH EACH OF THE SELLING
AGENT AND THE COMPANY CHOOSING ONE ARBITRATOR, AND THE CHOSEN ARBITRATORS CHOOSING THE THIRD ARBITRATOR). THE ARBITRATORS SHALL, IN THEIR AWARD, ALLOCATE ALL OF THE COSTS OF THE ARBITRATION, INCLUDING THE FEES OF THE ARBITRATORS AND THE REASONABLE
ATTORNEYS’ FEES OF THE PREVAILING PARTY, AGAINST THE PARTY WHO DID NOT PREVAIL. THE AWARD IN THE ARBITRATION SHALL BE FINAL AND BINDING. THE ARBITRATION SHALL BE GOVERNED BY THE FEDERAL ARBITRATION ACT, 9 U.S.C. SEC. 1-16, AND THE JUDGMENT UPON THE AWARD RENDERED BY THE ARBITRATORS MAY BE ENTERED BY ANY COURT HAVING JURISDICTION THEREOF. THE COMPANY AND THE PLACEMENT AGENT AGREE AND CONSENT TO PERSONAL
JURISDICTION, SERVICE OF PROCESS AND VENUE IN ANY FEDERAL OR STATE COURT WITHIN THE STATE AND COUNTY OF NEW YORK IN CONNECTION WITH ANY ACTION BROUGHT TO ENFORCE AN AWARD IN ARBITRATION. 

  
 20 

 14. Miscellaneous. No provision of this Agreement may be changed or terminated except by a
writing signed by the party or parties to be charged therewith. Unless expressly so provided, no party to this Agreement will be liable for the performance of any other party’s obligations hereunder. Either party hereto may waive compliance by
the other with any of the terms, provisions and conditions set forth herein; provided, however, that any such waiver shall be in writing specifically setting forth those provisions waived thereby. No such waiver shall be deemed to constitute or
imply waiver of any other term, provision or condition of this Agreement. Neither party may assign its rights or obligations under this Agreement to any other person or entity without the prior written consent of the other party. 

15. Entire Agreement; Severability. This Agreement together with any other agreement referred to herein supersedes all prior
understandings and written or oral agreements between the parties with respect to the Offering and the subject matter hereof. If any portion of this Agreement shall be held invalid or unenforceable, then so far as is reasonable and possible
(i) the remainder of this Agreement shall be considered valid and enforceable and (ii) effect shall be given to the intent manifested by the portion held invalid or unenforceable. 

16. Counterparts. This Agreement may be executed in multiple counterparts, each of which may be executed by less than all of the
parties and shall be deemed to be an original instrument which shall be enforceable against the parties actually executing such counterparts and all of which together shall constitute one and the same instrument. The exchange of copies of this
Agreement and of signature pages by facsimile transmission shall constitute effective execution and delivery of this Agreement as to the parties and may be used in lieu of the original Agreement for all purposes. Signatures of the parties
transmitted by facsimile shall be deemed to be their original signatures for all purposes. 
 [Signatures on following page.] 

  
 21 

 If the foregoing is in accordance with your understanding of the agreement by and between the
Company and the Placement Agent, kindly sign and return this Agreement, whereupon it will become a binding agreement between the Company and the Placement Agent in accordance with its terms. 

 

			
	GLOBEIMMUNE, INC.
		
	By:	 	/s/ Timothy C. Rodell
	 Name:
	 	Timothy C. Rodell, M.D.
	 Title:
	 	President and Chief Executive Officer

 Accepted and agreed to this 

27th day of January, 2014: 
  

			
	AEGIS CAPITAL CORP.
		
	By:	 	/s/ Eugene Terracciano
	 Name:
	 	Eugene Terracciano
	 Title:
	 	Director of Compliance

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00228-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00228-of-00352.parquet"}]]